Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease

Background. Non-alcoholic fatty liver disease (NAFLD) is the leading chronic hepatic condition worldwide and new approaches to management and treatment are limited.Summary. L-ornithine L-aspartate (LOLA) has hepatoprotective properties in patients with fatty liver of diverse etiology and results of...

Full description

Saved in:
Bibliographic Details
Main Authors: Roger F. Butterworth, Ali Canbay
Format: Article
Language:Russian
Published: Gastro LLC 2019-03-01
Series:Российский журнал гастроэнтерологии, гепатологии, колопроктологии
Subjects:
Online Access:https://www.gastro-j.ru/jour/article/view/322
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1823860134210699264
author Roger F. Butterworth
Ali Canbay
author_facet Roger F. Butterworth
Ali Canbay
author_sort Roger F. Butterworth
collection DOAJ
description Background. Non-alcoholic fatty liver disease (NAFLD) is the leading chronic hepatic condition worldwide and new approaches to management and treatment are limited.Summary. L-ornithine L-aspartate (LOLA) has hepatoprotective properties in patients with fatty liver of diverse etiology and results of a multicenter randomized clinical trial reveal that 12 weeks treatment with oral LOLA (6–9 g/d) results in a dose-related reduction in activities of liver enzymes and triglycerides together with significant improvements of liver/spleen CT ratios. A preliminary report described improvements of hepatic microcirculation in patients with nonalcoholic steatohepatitis (NASH) following treatment with LOLA. Mechanisms responsible for the beneficial effects of LOLA in NAFLD/NASH involve, in addition to its established ammonia-lowering effect, metabolic transformations of the LOLA-constituent amino acids L-ornithine and L-aspartate into L-glutamine, L-arginine, and glutathione. These metabolites have well-established actions implicated in the prevention of lipid peroxidation, improvement of hepatic microcirculation in addition to anti-inflammatory, and anti-oxidant properties.Key messages. (1) LOLA is effective for the treatment of key indices in NAFLD/NASH. (2) Mechanisms other than LOLA’s ammonia-lowering action have been postulated. (3) Further assessments in the clinical setting are now required.
format Article
id doaj-art-6cfd287a2ec943f1975a67eae32f2822
institution Kabale University
issn 1382-4376
2658-6673
language Russian
publishDate 2019-03-01
publisher Gastro LLC
record_format Article
series Российский журнал гастроэнтерологии, гепатологии, колопроктологии
spelling doaj-art-6cfd287a2ec943f1975a67eae32f28222025-02-10T16:14:35ZrusGastro LLCРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии1382-43762658-66732019-03-01291243010.22416/1382-4376-2019-29-1-24-30282Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver DiseaseRoger F. Butterworth0Ali Canbay1University of Montreal (St-Luc Hospital), Montreal, QCUniversity of Magdeburg (University Hospital), MagdeburgBackground. Non-alcoholic fatty liver disease (NAFLD) is the leading chronic hepatic condition worldwide and new approaches to management and treatment are limited.Summary. L-ornithine L-aspartate (LOLA) has hepatoprotective properties in patients with fatty liver of diverse etiology and results of a multicenter randomized clinical trial reveal that 12 weeks treatment with oral LOLA (6–9 g/d) results in a dose-related reduction in activities of liver enzymes and triglycerides together with significant improvements of liver/spleen CT ratios. A preliminary report described improvements of hepatic microcirculation in patients with nonalcoholic steatohepatitis (NASH) following treatment with LOLA. Mechanisms responsible for the beneficial effects of LOLA in NAFLD/NASH involve, in addition to its established ammonia-lowering effect, metabolic transformations of the LOLA-constituent amino acids L-ornithine and L-aspartate into L-glutamine, L-arginine, and glutathione. These metabolites have well-established actions implicated in the prevention of lipid peroxidation, improvement of hepatic microcirculation in addition to anti-inflammatory, and anti-oxidant properties.Key messages. (1) LOLA is effective for the treatment of key indices in NAFLD/NASH. (2) Mechanisms other than LOLA’s ammonia-lowering action have been postulated. (3) Further assessments in the clinical setting are now required.https://www.gastro-j.ru/jour/article/view/322l-ornithine l-aspartatenon-alcoholic fatty liver diseasenon-alcoholic steatohepatitishepatoprotectionantioxidanthepatic microcirculationglutamine
spellingShingle Roger F. Butterworth
Ali Canbay
Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease
Российский журнал гастроэнтерологии, гепатологии, колопроктологии
l-ornithine l-aspartate
non-alcoholic fatty liver disease
non-alcoholic steatohepatitis
hepatoprotection
antioxidant
hepatic microcirculation
glutamine
title Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease
title_full Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease
title_fullStr Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease
title_full_unstemmed Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease
title_short Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease
title_sort hepatoprotection by l ornithine l aspartate in non alcoholic fatty liver disease
topic l-ornithine l-aspartate
non-alcoholic fatty liver disease
non-alcoholic steatohepatitis
hepatoprotection
antioxidant
hepatic microcirculation
glutamine
url https://www.gastro-j.ru/jour/article/view/322
work_keys_str_mv AT rogerfbutterworth hepatoprotectionbylornithinelaspartateinnonalcoholicfattyliverdisease
AT alicanbay hepatoprotectionbylornithinelaspartateinnonalcoholicfattyliverdisease